PDF(Pubmed)
Abstract：
Type 1 diabetes (T1D) is a specific autoimmune disease related to genetic and autoimmune factors. Recent studies have found that the intestinal flora is one of the important environmental factors in the development of T1D. The gut microbiota is the largest microbiota in the human body and has a significant impact on material and energy metabolism. Related studies have found that the intestinal floras of T1D patients are unbalanced. Compared with normal patients, the abundance of beneficial bacteria is reduced, and various pathogenic bacteria are significantly increased, affecting the occurrence and development of diabetes. Medicinal and food homologous traditional Chinese medicine (TCM) has a multicomponent, multitarget, and biphasic regulatory effect. Its chemical composition can increase the abundance of beneficial bacteria, improve the diversity of the intestinal flora, reduce blood sugar, and achieve the purpose of preventing and treating T1D by regulating the intestinal flora and its metabolites. Therefore, based on a review of T1D, intestinal flora, and TCM derived from medicine and food, this review describes the relationship between T1D and the intestinal flora, as well as the research progress of TCM interventions for T1D through regulation of the intestinal flora. Medicine and food homologous TCM has certain advantages in treating diabetes and regulating the intestinal flora. It can be seen that there is still great research space and broad development prospects for the treatment of diabetes by regulating the intestinal flora with drug and food homologous TCM.
摘要：
1型糖尿病（T1D）是一种与遗传和自身免疫因素有关的特异性自身免疫性疾病。近年来研究发现肠道菌群是T1D发生发展的重要环境因素之一。肠道微生物群是人体中最大的微生物群，对物质和能量代谢具有重要影响。相关研究发现T1D患者肠道菌群不平衡。与正常患者相比,有益细菌的丰度减少，各种致病菌明显增多,影响糖尿病的发生和发展。药食同源中药具有多种成分,多目标,和双相调节作用。它的化学成分可以增加有益细菌的丰度，改善肠道菌群的多样性，降低血糖,并通过调节肠道菌群及其代谢产物达到防治T1D的目的。因此,根据对T1D的回顾，肠道菌群，从医药和食品中提取的中药，这篇综述描述了T1D与肠道菌群之间的关系，以及通过调节肠道菌群对T1D进行中医干预的研究进展。药食同源中药在治疗糖尿病和调节肠道菌群方面具有一定的优势。可见,用药食同源中药调节肠道菌群治疗糖尿病仍有很大的研究空间和广阔的发展前景。
